Cited 0 time in
Phospholipase D and Its Essential Role in Cancer
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Cho, Ju Hwan | - |
| dc.contributor.author | Han, Joong-Soo | - |
| dc.date.accessioned | 2022-07-12T23:55:02Z | - |
| dc.date.available | 2022-07-12T23:55:02Z | - |
| dc.date.issued | 2017-11 | - |
| dc.identifier.issn | 1016-8478 | - |
| dc.identifier.issn | 0219-1032 | - |
| dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/151277 | - |
| dc.description.abstract | The role of phospholipase D (PLD) in cancer development and management has been a major area of interest for researchers. The purpose of this mini-review is to explore PLD and its distinct role during chemotherapy including anti-apoptotic function. PLD is an enzyme that belongs to the phospholipase super family and is found in a broad range of organisms such as viruses, yeast, bacteria, animals, and plants. The function and activity of PLD are widely dependent on and regulated by neurotransmitters, hormones, small monomeric GTPases, and lipids. A growing body of research has shown that PLD activity is significantly increased in cancer tissues and cells, indicating that it plays a critical role in signal transduction, cell proliferation, and anti-apoptotic processes. In addition, recent studies show that PLD is a downstream transcriptional target of proteins that contribute to inflammation and carcinogenesis such as Sp1, NF kappa B, TCF4, ATF-2, NFATc2, and EWS-Fli. Thus, compounds that inhibit expression or activity of PLD in cells can be potentially useful in reducing inflammation and sensitizing resistant cancers during chemotherapy. | - |
| dc.format.extent | 9 | - |
| dc.language | 영어 | - |
| dc.language.iso | ENG | - |
| dc.publisher | 한국분자세포생물학회 | - |
| dc.title | Phospholipase D and Its Essential Role in Cancer | - |
| dc.type | Article | - |
| dc.publisher.location | 대한민국 | - |
| dc.identifier.doi | 10.14348/molcells.2017.0241 | - |
| dc.identifier.scopusid | 2-s2.0-85049763615 | - |
| dc.identifier.wosid | 000418528300001 | - |
| dc.identifier.bibliographicCitation | Molecules and Cells, v.40, no.11, pp 805 - 813 | - |
| dc.citation.title | Molecules and Cells | - |
| dc.citation.volume | 40 | - |
| dc.citation.number | 11 | - |
| dc.citation.startPage | 805 | - |
| dc.citation.endPage | 813 | - |
| dc.type.docType | Review | - |
| dc.identifier.kciid | ART002314147 | - |
| dc.description.isOpenAccess | N | - |
| dc.description.journalRegisteredClass | sci | - |
| dc.description.journalRegisteredClass | scie | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.description.journalRegisteredClass | kci | - |
| dc.relation.journalResearchArea | Biochemistry & Molecular Biology | - |
| dc.relation.journalResearchArea | Cell Biology | - |
| dc.relation.journalWebOfScienceCategory | Biochemistry & Molecular Biology | - |
| dc.relation.journalWebOfScienceCategory | Cell Biology | - |
| dc.subject.keywordPlus | PHOSPHATIDIC-ACID | - |
| dc.subject.keywordPlus | CELL INVASION | - |
| dc.subject.keywordPlus | MAST-CELLS | - |
| dc.subject.keywordPlus | D ISOZYMES | - |
| dc.subject.keywordPlus | EXPRESSION | - |
| dc.subject.keywordPlus | ISOFORM | - |
| dc.subject.keywordPlus | INFLAMMATION | - |
| dc.subject.keywordPlus | CHEMOTHERAPY | - |
| dc.subject.keywordPlus | ACTIVATION | - |
| dc.subject.keywordPlus | DESIGN | - |
| dc.subject.keywordAuthor | anti-cancer drug | - |
| dc.subject.keywordAuthor | apoptosis | - |
| dc.subject.keywordAuthor | cancer | - |
| dc.subject.keywordAuthor | inhibitor | - |
| dc.subject.keywordAuthor | PLD | - |
| dc.identifier.url | http://www.molcells.org/journal/view.html?doi=10.14348/molcells.2017.0241 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1366
COPYRIGHT © 2024 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
